ENANTA PHARMACEUTICALS, INC Other Noncash Income (Expense)
ENANTA PHARMACEUTICALS, INC (ENTA) reported Other Noncash Income (Expense) of $0 for the 12-month period ending 2023-09-30, per its 10-K filed 2023-11-22.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2023-11-22
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2020-09-30 was $0.00, a 100.00% decline year-over-year.
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2019-12-31 was $2.00K.
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2019-09-30 was $12.00K.
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for the quarter ending 2019-06-30 was $0.00.
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2023 was $0.00.
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2021 was $97.00K, a 90.20% increase from fiscal 2020.
- ENANTA PHARMACEUTICALS, INC other noncash income (expense) for fiscal 2020 was $51.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2023-09-30 | $0.00 10-K · filed 2023-11-22 | |||
| 2022-09-30 | $0.00 10-K · filed 2023-11-22 | |||
| 2021-09-30 | $97.00K 10-K · filed 2023-11-22 | |||
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-11-23 | $51.00K 10-K · filed 2022-11-23 | ||
| 2020-06-30 | $51.00K 10-Q · filed 2021-08-09 | |||
| 2019-12-31 | $2.00K 10-Q · filed 2021-02-09 | $14.00K derived: sum of 2 quarters · filed 2021-11-24 | $14.00K derived: sum of 3 quarters · filed 2021-11-24 | $16.00K derived: sum of 4 quarters · filed 2021-11-24 |
| 2019-09-30 | $12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-11-24 | $12.00K derived: sum of 2 quarters · filed 2021-11-24 | $14.00K derived: sum of 3 quarters · filed 2021-11-24 | -$25.00K 10-K · filed 2021-11-24 |
| 2019-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-08-10 | $2.00K derived: sum of 2 quarters · filed 2020-08-10 | -$37.00K 10-Q · filed 2020-08-10 | -$46.00K derived: sum of 4 quarters · filed 2020-11-25 |
| 2019-03-31 | $2.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-05-11 | -$37.00K 10-Q · filed 2020-05-11 | -$46.00K derived: sum of 3 quarters · filed 2020-11-25 | -$46.00K derived: sum of 4 quarters · filed 2020-11-25 |
| 2018-12-31 | -$39.00K 10-Q · filed 2020-02-10 | -$48.00K derived: sum of 2 quarters · filed 2020-11-25 | -$48.00K derived: sum of 3 quarters · filed 2020-11-25 | |
| 2018-09-30 | -$9.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-11-25 | -$9.00K derived: sum of 2 quarters · filed 2020-11-25 | $75.00K 10-K · filed 2020-11-25 | |
| 2018-06-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-08-09 | $84.00K 10-Q · filed 2019-08-09 | ||
| 2018-03-31 | $84.00K 10-Q · filed 2019-05-10 | |||
| 2016-09-30 | -$34.00K 10-K · filed 2018-11-29 | |||
| 2015-09-30 | $35.00K 10-K · filed 2017-12-11 | |||
| 2014-09-30 | -$2.00K 10-K · filed 2016-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |